Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Twist Bioscience Corporation (TWST)

174.69 +1.24 (+0.71%)
As of 12:21:28 PM EDT. Market Open.
Trade TWST on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Emily Marine Leproust Ph.D.
Co-Founder, Board Chair & CEO 1.78M -- 1973
Dr. Patrick John Finn Ph.D.
President & COO 1.27M -- 1972
Mr. Adam Laponis
Chief Financial Officer 850.69k -- 1977
Mr. Dennis Cho J.D.
Chief Legal Officer & Corporate Secretary 749.01k -- 1971
Ms. Paula Green
Senior Vice President of Human Resources 778.32k -- 1968
Mr. Robert F. Werner
VP & Chief Accounting Officer -- -- 1973
Mr. Siyuan Chen
Chief Technology Officer -- -- --
Dr. Michael Fero Ph.D.
Chief Information Officer -- -- --
Dr. Colby Souders Ph.D.
Chief Scientific Officer -- -- --
Ms. Nicole Moreno
Senior Vice President of Sales & Support -- -- --

Twist Bioscience Corporation

681 Gateway Boulevard
South San Francisco, CA 94080
United States
800 719 0671 https://www.twistbioscience.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
979

Description

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Twist Bioscience Corporation’s ISS Governance QualityScore as of October 1, 2026 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2026 at 12:30 PM UTC

Twist Bioscience Corporation Earnings Date

Recent Events

August 5, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 3, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 18, 2026 at 12:00 AM UTC

S-3ASR: Offering Registrations

May 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 26, 2026 at 12:00 AM UTC

10-Q/A: Periodic Financial Reports

February 17, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 2, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 6, 2026 at 12:00 AM UTC

ARS: Annual Report to Shareholders

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: